🚀
Enjoy a 7-Day Free Trial Thru May 04, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
LadRx Corp (OTCPK:LADX)
News
LadRx Corp
OTCPK
:LADX (USA) Â
$ 2.35
+0.1 (+4.44%)
10:08 PM EST
P/E:
At Loss
P/B:
10.68
Market Cap:
$ 1.16M
Enterprise V:
$ -923.00K
Volume:
215.00
Avg Vol (2M):
907.00
Warning! GuruFocus detected 1 Medium warning sign with LADX.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
215.00
Market Cap $:
1.16M
PE Ratio:
At Loss
Avg Vol (2M):
907.00
Enterprise Value $:
-923.00K
PB Ratio:
10.68
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
LadRx Corp (OTCPK:LADX) Stock News, Headlines & Updates
LadRx Corp Stock News from GuruFocus
Total 60
1
2
Feb 14, 2024
CytRx Corp To Hold Town Hall for Stockholders Call Transcript
GuruFocus Research
•
9:57pm
Aug 10, 2020
CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders
PRNewswire
•
7:01am
Jul 21, 2020
CytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
PRNewswire
•
11:02am
Jun 29, 2020
CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease
PRNewswire
•
11:02am
Apr 29, 2020
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease
PRNewswire
•
3:02pm
Mar 10, 2020
CytRx Corporation Provides Update on Management Change
PRNewswire
•
11:02am
Jan 29, 2020
CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin
PRNewswire
•
11:01am
Aug 09, 2019
CytRx Corporation Reports Second Quarter 2019 Financial Results
PRNewswire
•
11:01am
Jul 22, 2019
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
PRNewswire
•
11:09am
May 31, 2019
CytRx Corporation to Commence Trading on OTCQB Venture Market
PRNewswire
•
11:02am
May 15, 2019
CytRx Corporation Reports First Quarter 2019 Financial Results
PRNewswire
•
11:04am
May 08, 2019
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
PRNewswire
•
11:02am
May 02, 2019
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
PRNewswire
•
11:03am
Apr 29, 2019
CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
PRNewswire
•
11:03am
Mar 29, 2019
CytRx Corporation Reports 2018 Financial Results
PRNewswire
•
11:01am
Mar 12, 2019
CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
PRNewswire
•
11:04am
Feb 13, 2019
CytRx Corporation Leads Revival of Cytotoxic Therapies with LADRâ„¢ Technology Targeting Delivery Directly to the Tumor
PRNewswire
•
11:18am
Feb 11, 2019
CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
PRNewswire
•
11:33am
Feb 06, 2019
CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
PRNewswire
•
11:05am
Jan 14, 2019
CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
PRNewswire
•
11:13am
Dec 21, 2018
CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADRâ„¢ Drug Candidates and Accompanying Companion Diagnostic
PRNewswire
•
11:04am
Nov 28, 2018
CytRx Corporation to Present at the 11th Annual LD Micro Main Event
PRNewswire
•
11:06am
Nov 08, 2018
CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
PRNewswire
•
11:10am
Nov 02, 2018
CytRx Corporation Reports Third Quarter 2018 Financial Results
PRNewswire
•
11:03am
Oct 31, 2018
Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
PRNewswire
•
11:07am
Oct 29, 2018
CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
PRNewswire
•
11:06am
Sep 25, 2018
CytRx Corporation to Present at the 2018 MicroCap Conference
PRNewswire
•
11:14am
Sep 13, 2018
CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
PRNewswire
•
11:09am
Aug 27, 2018
CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018
PRNewswire
•
11:05am
Aug 06, 2018
CytRx Corporation Reports Second Quarter 2018 Financial Results
PRNewswire
•
11:05am
Aug 01, 2018
CytRx Corporation Pays Off Balance of Outstanding Debt
PRNewswire
•
11:32am
Jul 30, 2018
CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018
PRNewswire
•
11:14am
Jul 25, 2018
CytRx Announces Centurion BioPharma Corporation's Filing of a Provisional Patent Application
PRNewswire
•
11:08am
Jul 23, 2018
CytRx Corporation Announces Expiration of Outstanding Warrants
PRNewswire
•
11:13am
Jul 16, 2018
CytRx Corporation to Present at the Singular Research Summer Solstice 2018 Conference
PRNewswire
•
11:08am
Jun 28, 2018
CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial
PRNewswire
•
11:10am
Jun 25, 2018
CytRx Corporation Joins Russell Microcap® Index
PRNewswire
•
11:10am
Jun 21, 2018
CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology
PRNewswire
•
11:05am
Jun 07, 2018
CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting
PRNewswire
•
11:05am
Jun 04, 2018
CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADRâ„¢ Albumin Binding Ultra-High Potency Oncology Drug Candidates
PRNewswire
•
11:11am
Total 60
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news